Comparing the current results to its competitors, Avadel Pharmaceuticals Plc reported Revenue increase in the 3 quarter 2025 by 55.34 % year on year. The sales growth was above Avadel Pharmaceuticals Plc's competitors' average revenue growth of 11.88 %, achieved in the same quarter.
Avadel Pharmaceuticals Plc's Comment on Competition and Industry Peers
The company operates in a highly competitive pharmaceutical and biotechnology industry, facing competition from academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology firms. Competitors include those with approved or developing niche branded or generic specialty pharmaceutical products or drug delivery platforms. Technological advancements or the development of improved or differentiated products by competitors may impact the company's product competitiveness. Specifically, the company's product LUMRYZ competes with twice-nightly oxybate formulations and daytime wake-promoting agents such as lisdexamfetamine, dextroamphetamine, methylphenidate, amphetamine, modafinil, armodafinil, solriamfetol, and pitolisant. LUMRYZ may also face competition from manufacturers of generic twice-nightly oxybate formulations. In January 2023, Hikma Pharmaceuticals plc launched an authorized generic version of Jazz Pharmaceuticals plc’s Xyrem (sodium oxybate). The company relies on patent protection, trade secrets, know-how, technological innovations, and licensing opportunities to maintain its competitive position but acknowledges that its patent rights are uncertain and subject to challenge or invalidation by third parties.
Due to outstanding performance in Overall company, revenue grew by 55.34 % Avadel Pharmaceuticals Plc improved its market share, to approximately 0.72 %.
September 3, 2024
Rise and Shine: Impact of Once-Nightly LUMRYZ on Narcoleptic Patient Preference and Avadel Pharmaceuticals In the relentless pursuit of alleviating the burdens of narcolepsy, Avadel Pharmaceuticals has forged a significant path forward with its novel formulation, LUMRYZ. The recent publication of the RESTORE data brings forth compelling insights into the efficacy and patient preference of this once-nightly extended-release oral suspension compared to the traditional twice-nightly oxybate regimens. Understanding the Narcoleptic Challenge Narcolepsy is a chronic neurological disorder characterized by the brain s inability to regulate sleep-wake cycles, resulting in excessive daytime sleepiness and disrupted n...
August 20, 2024
In the year of Our Lord, Two Thousand and Twenty-Four, as the march of medical science continues to unfold, it is with great fervour that we report developments in the field of pharmacotherapy for individuals afflicted with the malaise of narcolepsy. Avadel Pharmaceuticals plc, a biopharmaceutical entity dedicated to the art of medicine and the enhancement of human life, has recently announced a most significant publication in the venerable journal Clinical Therapeutics . The paper addresses a post-hoc analysis stemming from the pivotal Phase 3 REST-ON clinical trial, elucidating the potential of LUMRYZ a formulation of sodium oxybate to effectuate not only symptomatic relief from the intractable drowsi...
May 22, 2024
At the prestigious SLEEP 2024 Conference, Avadel Pharmaceuticals unveiled compelling new insights related to their flagship extended-release oral suspension drug, LUMRYZ (sodium oxybate). This year, an impressive 11 accepted abstracts presented at the conference reinforced the clinical benefits, patient satisfaction, and overall preference for LUMRYZ, providing fresh momentum in the field of sleep disorder treatments. LUMRYZ: A Game-Changing Therapy for Narcolepsy and Sleep Disorders LUMRYZ, known scientifically as sodium oxybate, stands out as a next-generation treatment for narcolepsy patients. Narcolepsy, characterized by excessive daytime sleepiness and sudden muscle weakness (cataplexy), is a chronic ne...
Publicly Traded Peers of Avadel Pharmaceuticals Plc
Evoke Pharma Inc Share Performance
+2.90%
30 Days
Evoke Pharma Inc
Profile
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
Enveric Biosciences Inc's business model centers around the development and commercialization of innovative cannabinoid medicines and therapies to address various medical conditions, primarily focusing on cancer-related symptoms and improving patient outcomes. The company aims to leverage its expertise in the pharmaceutical industry to advance its pipeline, obtain regulatory approvals, and establish strategic partnerships for the distribution and sale of its products.
Cormedix Inc operates on a business model centered around the research, development, and commercialization of innovative pharmaceutical products for the prevention and treatment of infectious and inflammatory diseases. The company focuses on utilizing its expertise in antimicrobial and immunological technology to address unmet medical needs. By leveraging collaborations, partnerships, and regulatory approvals, Cormedix aims to bring its products to market and improve healthcare outcomes for patients.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Bullfrog Ai Holdings Inc utilizes artificial intelligence technology to develop and provide advanced solutions for businesses. Their business model focuses on offering AI-powered products and services to help companies optimize their operations and decision-making processes.
Sources:
Avadel Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Avadel Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
